AIHW logo
METEOR logo
Our sites
AIHW GEN Aged Care Data Aboriginal and Torres Strait Islander
Health Performance Framework
Indigenous Mental Health and
Suicide Prevention Clearinghouse
Australian Mesothelioma Registry Housing data Regional Insights for Indigenous Communities
Contact FAQs
  • Find metadata
    • Find metadata
    • Getting started
    • Data set specifications
    • Indicator sets
    • Data quality statements
    • Data dictionary archives
  • Metadata management
    • Metadata management
    • Data standards
    • Registration authorities
    • Registration statuses
  • How to use METEOR
    • How to use METEOR
    • First steps
    • Using My Page
    • Downloading and printing
    • FAQs
    • About METEOR
  • Learn about metadata
    • Learn about metadata
    • Metadata explained
    • How to create metadata
    • Metadata development resources

Person—renal disease therapy, code N

Identifying and definitional attributes

Metadata item type:Help on this termData Element
Short name:Help on this termRenal disease therapy
METEOR identifier:Help on this term270264
Registration status:Help on this term
  • Health, Standard 01/03/2005
Definition:Help on this termThe therapy the person is receiving for renal disease, as represented by a code.
Data Element Concept:Person—renal disease therapy

Value domain attributes

Representational attributes

Representation class:Help on this termCode
Data type:Help on this termNumber
Format:Help on this termN
Maximum character length:Help on this term1
Permissible values:Help on this term
ValueMeaning
1Drugs for modification of renal disease
2Drugs for treatment of complications of renal disease
3Peritoneal dialysis
4Haemodialysis
5Functioning renal transplant

Collection and usage attributes

Guide for use:Help on this term

CODE 1     Drugs for modification of renal disease

This code is used to indicate drugs for modification of renal disease, includes drugs intended to slow progression of renal failure. Examples include antiproteinurics such as angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor antagonists (ATRA) and immunosuppressants.

CODE 2     Drugs for treatment of complications of renal disease

This code is used to indicate drugs for the treatment of the complications of renal disease. Examples include antihypertensive agents and drugs that are intended to correct biochemical imbalances caused by renal disease (e.g. loop diuretics, ACEI, erythropoietin, calcitriol, etc).

CODE 3     Peritoneal dialysis

This code is used to indicate peritoneal dialysis, chronic peritoneal dialysis, delivered at home, at a dialysis satellite centre or in hospital.

CODE 4     Haemodialysis

This code is used to indicate haemodialysis, chronic haemodialysis delivered at home, at a dialysis satellite centre or in hospital.

CODE 5     Functioning renal transplant

This code is used to indicate functioning renal transplant, the presence of a functioning renal transplant.

Data element attributes

Collection and usage attributes

Guide for use:Help on this termMore than one code can be recorded.
Collection methods:Help on this termTo be collected on commencement of treatment and regularly reviewed.

Source and reference attributes

Submitting organisation:Help on this termCardiovascular Data Working Group
Origin:Help on this termCaring for Australians with Renal Impairment Guidelines. Australian Kidney Foundation

Relational attributes

Related metadata references:Help on this term
Supersedes PDFRenal disease therapy, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (17.5 KB) No registration status
Implementation in Data Set Specifications:Help on this term
All attributes +

Cardiovascular disease (clinical) DSS
Health, Superseded 15/02/2006

DSS specific attributes +

DSS specific information:

Nephrotoxic agents (including radiocontrast) should be avoided where possible.
Drugs that impair auto-regulation of glomerular filtration rate (GFR) (NSAIDs, COX-2, ACEI, ATRA) should be used with caution in renal impairment, particularly when patients are acutely unwell for other reasons (sepsis, peri-operative etc).

Although combination ACEI and diuretic can be a very potent and efficacious means of reducing blood pressure (and thereby slowing progression), either drug should be introduced individually and carefully in a patient with underlying renal impairment. At the very least, diuretic therapy should be held or reduced when commencing an ACEI in a patient with renal impairment. Combination therapy with ACEI, diuretics and NSAIDs or COX-2 may be particularly harmful.

Drugs, which are primarily excreted by the kidney (e.g. metformin, sotalol, cisapride, etc.) need to be used with caution in patients with renal impairment. The calculated GFR needs to be determined and the dose reduced or the drug avoided as appropriate.


Cardiovascular disease (clinical) DSS
Health, Superseded 04/07/2007

DSS specific attributes +

DSS specific information:

Nephrotoxic agents (including radiocontrast) should be avoided where possible.
Drugs that impair auto-regulation of glomerular filtration rate (GFR) (NSAIDs, COX-2, ACEI, ATRA) should be used with caution in renal impairment, particularly when patients are acutely unwell for other reasons (sepsis, peri-operative etc).

Although combination ACEI and diuretic can be a very potent and efficacious means of reducing blood pressure (and thereby slowing progression), either drug should be introduced individually and carefully in a patient with underlying renal impairment. At the very least, diuretic therapy should be held or reduced when commencing an ACEI in a patient with renal impairment. Combination therapy with ACEI, diuretics and NSAIDs or COX-2 may be particularly harmful.

Drugs, which are primarily excreted by the kidney (e.g. metformin, sotalol, cisapride, etc.) need to be used with caution in patients with renal impairment. The calculated GFR needs to be determined and the dose reduced or the drug avoided as appropriate.


Cardiovascular disease (clinical) DSS
Health, Superseded 22/12/2009

DSS specific attributes +

DSS specific information:

Nephrotoxic agents (including radiocontrast) should be avoided where possible.
Drugs that impair auto-regulation of glomerular filtration rate (GFR) (NSAIDs, COX-2, ACEI, ATRA) should be used with caution in renal impairment, particularly when patients are acutely unwell for other reasons (sepsis, peri-operative etc).

Although combination ACEI and diuretic can be a very potent and efficacious means of reducing blood pressure (and thereby slowing progression), either drug should be introduced individually and carefully in a patient with underlying renal impairment. At the very least, diuretic therapy should be held or reduced when commencing an ACEI in a patient with renal impairment. Combination therapy with ACEI, diuretics and NSAIDs or COX-2 may be particularly harmful.

Drugs, which are primarily excreted by the kidney (e.g. metformin, sotalol, cisapride, etc.) need to be used with caution in patients with renal impairment. The calculated GFR needs to be determined and the dose reduced or the drug avoided as appropriate.


Cardiovascular disease (clinical) DSS
Health, Superseded 01/09/2012

DSS specific attributes +

DSS specific information:

Nephrotoxic agents (including radiocontrast) should be avoided where possible.
Drugs that impair auto-regulation of glomerular filtration rate (GFR) (NSAIDs, COX-2, ACEI, ATRA) should be used with caution in renal impairment, particularly when patients are acutely unwell for other reasons (sepsis, peri-operative etc).

Although combination ACEI and diuretic can be a very potent and efficacious means of reducing blood pressure (and thereby slowing progression), either drug should be introduced individually and carefully in a patient with underlying renal impairment. At the very least, diuretic therapy should be held or reduced when commencing an ACEI in a patient with renal impairment. Combination therapy with ACEI, diuretics and NSAIDs or COX-2 may be particularly harmful.

Drugs, which are primarily excreted by the kidney (e.g. metformin, sotalol, cisapride, etc.) need to be used with caution in patients with renal impairment. The calculated GFR needs to be determined and the dose reduced or the drug avoided as appropriate.


Cardiovascular disease (clinical) NBPDS
Health, Superseded 17/10/2018

DSS specific attributes +

DSS specific information:

Nephrotoxic agents (including radiocontrast) should be avoided where possible.
Drugs that impair auto-regulation of glomerular filtration rate (GFR) (NSAIDs, COX-2, ACEI, ATRA) should be used with caution in renal impairment, particularly when patients are acutely unwell for other reasons (sepsis, peri-operative etc).

Although combination ACEI and diuretic can be a very potent and efficacious means of reducing blood pressure (and thereby slowing progression), either drug should be introduced individually and carefully in a patient with underlying renal impairment. At the very least, diuretic therapy should be held or reduced when commencing an ACEI in a patient with renal impairment. Combination therapy with ACEI, diuretics and NSAIDs or COX-2 may be particularly harmful.

Drugs, which are primarily excreted by the kidney (e.g. metformin, sotalol, cisapride, etc.) need to be used with caution in patients with renal impairment. The calculated GFR needs to be determined and the dose reduced or the drug avoided as appropriate.


Cardiovascular disease (clinical) NBPDS
Health, Standard 17/10/2018

DSS specific attributes +

DSS specific information:

Nephrotoxic agents (including radiocontrast) should be avoided where possible.
Drugs that impair auto-regulation of glomerular filtration rate (GFR) (NSAIDs, COX-2, ACEI, ATRA) should be used with caution in renal impairment, particularly when patients are acutely unwell for other reasons (sepsis, peri-operative etc).

Although combination ACEI and diuretic can be a very potent and efficacious means of reducing blood pressure (and thereby slowing progression), either drug should be introduced individually and carefully in a patient with underlying renal impairment. At the very least, diuretic therapy should be held or reduced when commencing an ACEI in a patient with renal impairment. Combination therapy with ACEI, diuretics and NSAIDs or COX-2 may be particularly harmful.

Drugs, which are primarily excreted by the kidney (e.g. metformin, sotalol, cisapride, etc.) need to be used with caution in patients with renal impairment. The calculated GFR needs to be determined and the dose reduced or the drug avoided as appropriate.


Help
Downloading

The download may take a while, please wait.

Do not refresh the screen until the download is complete.

<Title>

<body>
<footer>
  • View
  • Show more
  • Print view
  • Download
  • Word™
  • Pdf
  • Advanced Download
  • Review
  • Compare items
© Australian Institute of Health and Welfare
Version 1.0.0+20220809.3